by admin | Oct 13, 2018 | All News, Industry News
– First medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis based on an intra-patient comparison – – Only medicine that can be self-administered subcutaneously once weekly, every two weeks or every four weeks for hemophilia A with...
by admin | Aug 23, 2018 | Advocacy News, All News
(Greenville, South Carolina) — On Thursday, August 16, and Friday, August 17, 2018, approximately 47 policy experts, government officials, medical professionals, and bleeding disorders advocates, met in Columbia, South Carolina, to address access to healthcare issues...
by admin | Mar 28, 2018 | All News, Research News
The Hemophilia Treatment Centers (HTCs) Network Investigators, a group of researchers from several U.S. HTCs, recently published a study on disparities associated with bleeding symptoms, age at diagnosis and provider interventions for females with bleeding disorders....
by admin | Mar 28, 2018 | Advocacy News, All News
The Patient Access Network (PAN) Foundation has opened a new patient insurance premium assistance program for individuals with hemophilia. PAN is an independent, national 501(c)(3) organization dedicated to helping federally and commercially insured people living with...
by admin | Nov 22, 2017 | All News
® (EMICIZUMAB-KXWH) FOR HEMOPHILIA A WITH INHIBITORS – First new medicine in nearly 20 years to treat people with hemophilia A with inhibitors – – HEMLIBRA substantially reduced bleeds in adults and children – – Only medicine that can be self-administered once weekly...
